Guangdong Shengpu Life Technology Co., Ltd., established on 2006-10-27, Business scope includes natural science research and experimental development;Life Engineering Project Development;Health Sciences Program Research,to develop;Technology Promotion of Research Results of Health Science Projects;Health Sciences Program Research Transfer;Research and development of biological products(Does not include licensed operations);Biomedical Technology Research;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Research on water treatment equipment,to develop;Technology development and technical services of artificial intelligence algorithm software;AI Hardware Sales;electronic,Communication and Automatic Control Technology Research,to develop;Investment Advisory Services;Energy saving technology development service;Energy-saving technical consultation,communication service;Energy-saving technology transfer service;E-commerce information consultation;Electronic equipment engineering installation service;Special Equipment Sales;high-tech investment,operate(Does not include licensed operations,Projects prohibited by laws and regulations shall not be operated);Commodity wholesale trade(Except for licensed and approved products);Commodity retail trade(Except for licensed and approved products);Internet Merchandise Sales(Except for licensed and approved products);Import and export(Excluding franchised products);Technology Import and Export;

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Industry Academic Cooperation Foundation Hallym University is a private company headquartered in the South Korea. The firm provides office support services.

Under the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. Having successfully launched its first product 『NORUMO』 on July 1, 1957, they moved to a new plant site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for production of aluminum hydroxide gel. Entering the 1960's, they quickly expanded under management modernization with new product development and sought multilateral changeover in management in the 19R70's. Particularly, the birth of Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG PHARM. After founding Neusiline composition plant in Yongin in November 1972, they went through business opening in 1742 and became the 125th listed company in Korea.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands.

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

Beijing Jiukeshu International Medical Technology Research Center Daqing Branch, established on 2006-07-20, Business scope includes Chinese and Western medicine and acupuncture,Massage Technology Development,training,consultation service;Undertake the exhibition,Corporate Image Planning.

Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea.

Macrogen is a biotechnology company. Their precision medicine predicts, diagnoses, and treats diseases by integrating genetic data into health records. They provide DNA sequencing services, covid-19 test kits, an on-site testing lab, and personal health that offerings based on personal genome sequencing and gut microbiome tests.

BioNote, Inc. develops veterinary diagnostic composition. Its products include bovine, porcine, avian, canine and feline. The company was founded in March 2003 and is headquartered in Hwaseong, South Korea.